Physician profile
Steven P Gradney
NPI 1477743839
$925,885.45
in general payments reported to CMS, 2019-2025
14 companies · $356K in 2025
The $356K reported for 2025 was more than what 99% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $588 · 2021: $10K · 2022: $95K · 2023: $165K · 2024: $298K · 2025: $356K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $368K · Travel and Lodging: $154K · Honoraria: $136K · Consulting Fee: $127K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $367,766.00 |
| Travel and Lodging | $153,894.06 |
| Honoraria | $135,816.67 |
| Consulting Fee | $127,077.96 |
| Food and Beverage | $22,387.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,774.00 |
| Education | $128.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $362,407.74 | 2019-2025 | Xywav |
| Avadel Cns Pharmaceuticals, LLC | $248,109.77 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $142,567.78 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $105,435.22 | 2023-2025 | Sunosi |
| Lilly USA, LLC | $53,722.37 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $11,762.35 | 2021-2025 | Inspire |
| Zoll Respicardia, INC. | $782.95 | 2021-2025 | Remede System |
| Itamar Medical INC | $559.22 | 2022-2024 | Watchpatone |
| Idorsia Pharmaceuticals US INC | $353.18 | 2023-2024 | Quviviq |
| Sk Life Science, INC. | $121.70 | 2025 | Xcopri |
| Vanda Pharmaceuticals INC. | $21.71 | 2020 | |
| Gilead Sciences, INC. | $17.20 | 2019 | |
| Apria Healthcare LLC | $12.74 | 2021 | |
| Fisher & Paykel Healthcare INC | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gradney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.